<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01430117</url>
  </required_header>
  <id_info>
    <org_study_id>6045-PR-PRI-183</org_study_id>
    <secondary_id>2010-023950-35</secondary_id>
    <nct_id>NCT01430117</nct_id>
  </id_info>
  <brief_title>Biological Standardization of Poa Pratensis Allergen Extract</brief_title>
  <official_title>Biological Standardization of Poa Pratensis Allergen Extract to Determine the Biological Activity in Histamine Equivalent Prick (HEP) Units</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratorios Leti, S.L.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laboratorios Leti, S.L.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to determine the biologic activity of a Poa pratensis allergen&#xD;
      extract in histamine equivalent prick (HEP) units, in order to be used as in-house reference&#xD;
      preparation (IHRP).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open, unblinded and non-randomized biological assay. The study design is a slight&#xD;
      modification of the recommendations proposed by the Nordic Guidelines.&#xD;
&#xD;
      Four concentrations of Poa pratensis allergen extract, together with a positive and negative&#xD;
      control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline&#xD;
      solution, respectively, will be tested in every patient in duplicate on the volar surface of&#xD;
      the forearm.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Wheal size area (mm2) on the skin at the site of the puncture during the immediate phase.</measure>
    <time_frame>Test sites should be inspected and recorded 15-20 min after application</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Allergy to Grass Pollen</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Poa pratensis allergen extract at 4 different concentrations.&#xD;
Positive control.&#xD;
Negative control.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Four different concentrations of Poa pratensis allergen extract, positive control and negative control</intervention_name>
    <description>Four concentrations of Poa pratensis allergen extract, together with a positive and negative control will be tested in every patient in duplicate on the volar surface of the forearm.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. A documented positive case history with inhalation allergy (rhinitis and/or&#xD;
             rhinoconjunctivitis and/or asthma) related to Poa pratensis.&#xD;
&#xD;
          2. Subject has provided written informed consent, appropriately signed and dated by the&#xD;
             subject (or legal representative, if applicable).&#xD;
&#xD;
          3. Subject can be male or female of any race and ethnic group.&#xD;
&#xD;
          4. Age &gt; 18 years and &lt; 50 years at the study inclusion day.&#xD;
&#xD;
          5. Positive skin prick test with a standardized commercially available preparation of Poa&#xD;
             pratensis allergen extract. The skin prick test will be considered positive if the&#xD;
             test results in a wheal major diameter of at least 3 mm and at least the size of the&#xD;
             positive control. Positive skin prick test results are valid if performed within one&#xD;
             year prior to the inclusion of the subject in the study&#xD;
&#xD;
          6. A positive test for specific IgE to Poa pratensis(CAP-RAST ≥ 2). IgE results are valid&#xD;
             if performed within one year prior to the inclusion of the subject in the study.&#xD;
&#xD;
          7. Allergic symptoms during the pollen season of Poa pratensis.&#xD;
&#xD;
          8. Mean of the forearm major diameters of the wheals provoked by histamine&#xD;
             dihydrochloride (10 mg/ml) ≥ 3 mm.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Immunotherapy in the past 5 years with an allergen preparation known to interfere with&#xD;
             the allergen to be tested (e.g., grass group extracts).&#xD;
&#xD;
          2. Use of drugs that may interfere with the skin reactions (e.g., antihistamines). See&#xD;
             Appendix 1&#xD;
&#xD;
          3. Treatment with any of the following medications: tricyclic or tetracyclic&#xD;
             antidepressants, β-blockers or corticosteroids (&gt; 10 mg/day of prednisone or&#xD;
             equivalent).&#xD;
&#xD;
          4. Pregnancy.&#xD;
&#xD;
          5. Dermographism affecting the skin area at the test site at either study visit.&#xD;
&#xD;
          6. Atopic dermatitis affecting the skin area at the test site at either study visit.&#xD;
&#xD;
          7. Urticaria affecting the skin area at the test site at either study visit.&#xD;
&#xD;
          8. Participation in another clinical trial within the last month.&#xD;
&#xD;
          9. Subjects suffering from pathologies or conditions in which adrenalin is&#xD;
             contraindicated (heart disease, severe hypertension,...)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>María José Gómez</last_name>
    <role>Study Chair</role>
    <affiliation>Laboratorios LETI, S.L.Unipersonal</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>C.E. Virgen de la Cinta - Hospital Juan Ramón Jiménez</name>
      <address>
        <city>Huelva</city>
        <state>Andalucía</state>
        <zip>21003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marqués de Valdecilla</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <study_first_submitted>September 6, 2011</study_first_submitted>
  <study_first_submitted_qc>September 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2011</study_first_posted>
  <last_update_submitted>August 20, 2012</last_update_submitted>
  <last_update_submitted_qc>August 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 21, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immunotherapy</keyword>
  <keyword>Skin prick test</keyword>
  <keyword>Standardization</keyword>
  <keyword>Poa pratensis</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

